Sentien Biotechnologies said this week it received an Investigational New Drug approval for its SBI-101 drug-device combination product meant for treating individuals with acute kidney injury.
The multi-center, Phase 1/2 trial will be the the 1st for the company, and will examine its platform which uses a blood filtering device containing mesenchymal stromal cells, often found in bone marrow, for the controlled, sustained delivery of MSC secreted factors.
Read the whole story on our sister site, Drug Delivery Business
The post Sentien launches trial for drug-device combo for treating acute kidney injury appeared first on MassDevice.
from MassDevice http://ift.tt/2otmPwt
Cap comentari:
Publica un comentari a l'entrada